Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1995-06-01
1997-09-23
Martinell, James
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
536 235, C07H 2100, C12N 1511
Patent
active
056706340
ABSTRACT:
The invention provides oligonucleotides that inhibit the expression of .beta./A4 peptide of Alzheimer's disease and Down's syndrome, and further provides methods for reversing morphological changes caused in neuronal cells by .beta./A4 peptide.
REFERENCES:
patent: 5149798 (1992-09-01), Agrawal et al.
patent: 5151510 (1992-09-01), Stec et al.
patent: 5242932 (1993-09-01), Gandy et al.
patent: 5245022 (1993-09-01), Weis et al.
patent: 5316930 (1994-05-01), Loesch-Fries et al.
Camarata, P.L., et al., "Sustained release of nerve growth factor from biodegradable polymer microspheres," Neurosurgery 30:313-319 (1992).
Ernfors, P. et al., "A cell line producing recombinant nerve growth factor evokes growth respon ses in intrinsic and grafted central cholinergic neurons", Proc. Natl. Acad. Sci. USA86(12):4756-4760 (1989).
Friden, P. et al., "Blood-Brain Barrier Penetration and In-Vivo Activity of an NGF Conjugate," Science 30(3):313-319 (1992).
LeBlanc, A. et al., "Role of amyloid precursor protein (APP): study with antisense transfection of human neuroblastoma cells", J. Neuroscience Research 31(4):635-645 Apr. (1992).
Marotta, C. et al., "Overexpression of amyloid precursor protein A4 .beta.-amyloid immunoreactivity in genetically transformed cells: implications for a cellular model of Alzheimer amyloidosis", Proc. Natl. Acad. Sci. USA 86:337-341 Jan. (1989).
Milward, E. et al., "The amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth", Neuron 9(1):129-137 Jul. (1992).
Olson, L., "NGF and the treatment of Alzheimer's disease", Experimental Neurology 124:5-15 Nov. (1993).
Refolo, L. et al. "Nerve and epidermal growth factor induce the release of the Alzheimer amyloid precursor from PC12 cell cultures", Biochemical and Biophysical Research Communications 164(2): 664-670 Oct. (1989).
Shaw J-P et al., "Modified deoxyoligonucleotides stable to exonuclease degradation of serum", Nucleic Acid Research 19(4):747-750 (1991).
Tang J. et al., "Self-stabilized antisense oligodeoxynucleotide phosphorothioates: properties and anti-HIV activity", Nucleic Acid Research 21:2729-2735 Jun. (1993).
Kennell, Progr. Nucl. Acidx Res. Mol. Biol. 11; 259-262 (1971).
Syrjanen et al, Neuroscience Letters 130:89 (1991).
Suggs et al, Proc. Natl. Acad. Sci. USA 78:6613 (1981).
Marcus-Sekura, Anal. Biochem. 172:289 (1988).
Eguchi et al, Annu. Rev. Biochem. 60: 631 (1991).
Agrawal & Goodchild, "Oligodeoxynucleoside Methylphosphonates: Synthesis and Enzymic Degradation", Tetrahedron Lett. 28:3539-3542 (1987).
Beyreuther et al., "Amyloid precursor protein (APP) and beta A4 amyloid in Alzheimer's disease and Down syndrome", Prog. Clin Biol. Res. 379:159-182 (1992).
Cole et al., "The distribution of amyloid plaques in the cerebellum and brain stem in Down's syndrome and Alzheimer's disease: a light microscopical analysis", Acta Neuropathol 85:542-552 (1993).
Glenner & Wong, "Alzheimer's disease: intial report of the purification and characterization of a novel cerebrovascular amyloid protein", Biochem. Biophys. Res. Commun. 120:885-890 (May 16, 1984).
Glenner & Wong, "Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein", Biochem. Biophys. Res. Commun. 122:1131-1135 (Aug. 16, 1984).
Ikeda et al., "Evidence of amyloid beta-protein immunoreactive early plaque lesions in Down's syndrome brains", Lab Invest. 61:133-137 (1989).
Ikeda et al., "A study of the morphology and distribution of amyloid beta protein immunoreactive plaque and related lesions in the brains of Alzheimer's disease and adult Down's syndrome" Prog. Clin. Biol. Res. 317:313-323 (1989).
Kang et al., "The precursor of Alzheimer's disease Amyloid A4 protein resembles a cell-surface receptor" Nature 325:733-736 (Feb. 19, 1987).
Maestre et al , "Cell surface extensions associated with overexpression of Alzheimer beta/A4 amyloid", Brain Res. 599:64-72 (1992).
Majocha et al. "PC12 cells release stimulatory factors after transfection with beta/A4-C-terminal DNA of the Alzheimer amyloid precursor Protein", Mol. Chem. Neuropathol. 18:99-113 (1993).
Majocha et al., "Laminar-specific distribution and infrastructural detail of amyloid in the Alzheimer disease cortex visualized by computer-enhanced imaging of epitopes recognized by monoclonal antibodies", Proc. Natl. Acad. Sci. USA 85(16):6182-6186 (Aug. 1988).
Marotta et al., "Overexpression of amyloid precursor protein A4 (beta-amyloid) immunoreactivity in genetically transformed cells: implications for a cellular model of Alzheimer amyloidosis", Proc. Natl. Acad. Sci. USA 86:337-341 (Jan. 1989).
Marshall & Caruthers, "Phosphorodithioate DNA as a Potential Therapeutic Drug", Science 259:1564-1570 (Mar. 12, 1993)
Masters et al., "Amyloid plaque core protein in Alzheimer disease and Down syndrome", Proc. Natl. Acad. Sci. USA 82:4245-4249 (Jun. 1985)
Padmapriya & Agrawal, "Synthesis of Oligodeoxynucleoside Methylphosphonothioates", Bioorganic & Medicinal Chemistry Letters 3:761-764 (1993).
Patterson et al., "Mapping of the gene encoding the beta-amyloid precursor protein and its relationship to the Down syndrome region of chromosome 21", Proc. Natl. Acad. Sci. USA 85(21):8266-8270 (Nov. 1988).
Schneider & Benner, "Building Blocks for Oligonucleotide analogs with dimethylene-sulfide,-sulfoxide, and -sulfone groups replacing phosphodiester linkages", Tetrahedron Lett. 31:335-338 (1990).
Tate et al., "Disruption of circadian regulation by brain grafts that overexpress Alzheimer beta/A4 amyloid", Proc. Natl. Acad. Sci. 89(15):7090-7094 (Aug. 1992).
Uhlmann & Peyman, "Antisense Oligonucleotides: A New Therapeutic Principle", Chemical Reviews 90:543-584 (Jun. 1990).
Agrawal Sudhir
Majocha Ronald E.
Marotta Charles A.
Martinell James
The General Hospital Corporation
LandOfFree
Reversal of .beta./A4 amyloid peptide induced morphological chan does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Reversal of .beta./A4 amyloid peptide induced morphological chan, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reversal of .beta./A4 amyloid peptide induced morphological chan will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1939078